Disruptive bench-scale purification of lentivirus using affinity-liquid phase separation technology

Lentiviral vectors (LVs) are widely used viral vectors necessary for the production of several commercial cell and gene therapies. However, their innate fragility and cytotoxicity, due to their lipid bilayer and VSVG (vesicular stomatitis virus envelope glycoprotein) pseudotype, respectively, means that the manufacturing cost of these vectors is extremely high. Traditional downstream purification strategies are being commercially adapted for large and complex viruses.